ALT Levels in Women: What Your Number Changes About Your Treatment

What ALT Actually Measures (and Why the Lab's "Normal" Range May Not Apply to You)

ALT is an enzyme that lives primarily inside liver cells. When those cells are damaged or inflamed, ALT leaks into the bloodstream. Your clinician orders it to screen for hepatocellular injury, track known liver disease, and monitor drug safety. The number on your printed lab report looks straightforward, but the reference range printed beside it often is not.

Most clinical laboratories still use a combined male-and-female reference range of roughly 7 to 56 U/L, derived from studies that enrolled predominantly men. A landmark re-analysis published in Hepatology found that the sex-specific upper limit of normal for women should be closer to 19 U/L, not the 35 to 56 U/L range printed on most reports. That gap matters because a woman with an ALT of 30 U/L may read "within normal limits" on her printout while her liver is telling a different story.

Why Women Have Lower ALT at Baseline

Skeletal muscle is a secondary source of ALT, and women carry less lean muscle mass per kilogram of body weight than men, so baseline enzyme release is lower. Sex hormones also modulate ALT directly: estrogen appears to suppress hepatic ALT release, which is one reason post-menopausal women often see their ALT drift upward after estrogen levels fall, even without any new liver pathology.

What the Printed Range Gets Wrong

Because the printed normal goes up to 35 to 56 U/L, a woman with an ALT of 28 U/L may be reassured by a lab report saying "normal" when her value is actually 1.5 times a sex-appropriate upper limit of normal. The American Association for the Study of Liver Diseases (AASLD) has formally called for sex-specific reference intervals to be adopted universally. Until your lab updates its ranges, ask your clinician to interpret your ALT against the sex-specific threshold of approximately 19 to 25 U/L.

ALT Across Your Life Stages

Your hormonal status is not a footnote to ALT interpretation. It is part of the interpretation.

Reproductive Years (Roughly Ages 15 to 45)

During the menstrual cycle, ALT shows small fluctuations, but these are not clinically significant enough to require cycle-timed testing. What does matter is that women in their reproductive years with PCOS have a substantially elevated prevalence of metabolic-associated steatotic liver disease (MASLD, formerly called NAFLD). One meta-analysis found MASLD prevalence of approximately 35 to 70% in women with PCOS, compared with roughly 20 to 30% in the general female population. An ALT above the sex-specific ULN in a woman with PCOS should prompt liver imaging, not just a "watch and wait" response.

Trying to Conceive and Early Pregnancy

If you are trying to conceive and your ALT is elevated, that finding affects which fertility medications can be started safely. Letrozole and clomiphene citrate are both hepatically metabolized; prescribers typically want an ALT below 3× ULN before initiating either agent, though specific thresholds are not codified in ASRM guidelines and are clinician-dependent.

In the first trimester, mild ALT elevation (up to 2× ULN) occurs in some women with hyperemesis gravidarum and usually resolves as vomiting is controlled. ACOG Practice Bulletin 189 on nausea and vomiting of pregnancy notes transient hepatic enzyme elevation in severe cases.

Third Trimester and Intrahepatic Cholestasis of Pregnancy

A significant ALT spike in the third trimester, particularly when paired with itching on the palms and soles, is the classic presentation of intrahepatic cholestasis of pregnancy (ICP). ICP affects approximately 0.5 to 2% of pregnancies in the United States and carries a real risk of stillbirth if untreated. This is not a situation for medication adjustment; it requires urgent obstetric review and likely delivery planning. Ursodeoxycholic acid (15 mg/kg/day) is the standard treatment, though a large 2019 RCT (PITCHES trial) in The Lancet found it did not reduce adverse perinatal outcomes compared with placebo, raising active debate about its benefit.

Postpartum

Postpartum thyroiditis affects roughly 5 to 10% of women in the first year after delivery and can cause mild ALT elevation during the thyrotoxic phase. If your ALT is unexpectedly elevated at a postpartum visit, thyroid function tests (TSH, free T4) are worth checking alongside a lipid panel and glucose, especially if you have a personal or family history of autoimmune thyroid disease.

Perimenopause

Estrogen decline during perimenopause drives visceral fat accumulation even without weight gain, and visceral adiposity is the primary driver of MASLD. The Study of Women's Health Across the Nation (SWAN) found that liver fat increased significantly during the menopausal transition independent of total body weight. A woman in her late 40s whose ALT creeps from 18 to 32 U/L over two years deserves a dedicated metabolic workup, not reassurance that she is "still in the normal range" per the standard printout.

Post-Menopause

After menopause, the protective effect of endogenous estrogen on hepatic fat is gone. Women over 60 with obesity, type 2 diabetes, or metabolic syndrome are at meaningful risk for progression from MASLD to metabolic-associated steatohepatitis (MASH) and fibrosis. The AACE/ACE 2022 position statement on NAFLD/NASH recommends ALT monitoring as part of routine cardiometabolic screening in this population.

What a High ALT Means for Your Prescriptions

This is where ALT stops being academic. A high ALT changes what medications you can take, at what dose, and for how long.

The 3× ULN Rule

Most drug safety guidelines use multiples of the upper limit of normal rather than absolute values. The standard thresholds are:

| ALT Level | General Clinical Action | |---|---| | <3× ULN | Continue medication; monitor more frequently | | 3 to 5× ULN | Pause medication; recheck in 1 to 2 weeks | | >5× ULN | Stop medication; full hepatology workup | | >10× ULN + symptoms | Acute hepatotoxicity protocol; consider hospitalization |

Because the printed ULN for women is often inflated, applying these multiples to the sex-specific ULN of ~19 to 25 U/L changes the decision point. An ALT of 75 U/L is 3× the sex-specific ULN (25 × 3 = 75) but only 1.5× the commonly printed ULN of 56 U/L. That difference can mean the gap between continuing a medication and pausing it.

Metformin

Metformin is not significantly hepatotoxic, but it is commonly paused when ALT exceeds 3× ULN because active liver disease can impair lactate clearance and raise the theoretical risk of lactic acidosis. The FDA label for metformin states it is contraindicated in patients with hepatic impairment. For women with PCOS who rely on metformin for cycle regulation and insulin sensitization, an elevated ALT may therefore temporarily remove a cornerstone of their care plan, making the underlying MASLD a more urgent treatment target.

Statins

Statins are among the most commonly prescribed medications in perimenopausal and post-menopausal women for cardiovascular risk reduction. The 2022 ACC/AHA Cholesterol Guideline notes that clinically significant statin hepatotoxicity is rare (estimated incidence <0.001%), yet many prescribers reflexively pause statins when ALT rises. Paradoxically, statins may actually improve liver histology in MASLD, and a 2010 analysis in Hepatology found that statin use was associated with lower rates of fibrosis progression in patients with NASH. The current consensus: statins can be continued when ALT is below 3× ULN, even in the setting of MASLD, and routine ALT monitoring is no longer recommended for patients on stable statin therapy without symptoms.

GLP-1 Receptor Agonists

Semaglutide and tirzepatide are increasingly prescribed to women for weight management, PCOS-related insulin resistance, and type 2 diabetes. These drugs do not cause liver injury. They actively reduce hepatic steatosis. The ESSENCE trial (semaglutide in MASH) published in the New England Journal of Medicine in 2024 showed that 62.9% of participants receiving semaglutide 2.4 mg achieved MASH resolution without worsening fibrosis, compared with 34.3% on placebo. An elevated ALT is not a contraindication to starting a GLP-1 agonist; in many women with MASLD, it is actually a reason to prioritize one.

Hormonal Medications: Oral Contraceptives, HRT, and Tamoxifen

Oral contraceptives (OCs) cause mild, dose-dependent ALT elevation in some women through direct hepatic effects of synthetic estrogen. This is usually clinically insignificant but worth noting if you are tracking trends. If your ALT is already elevated at baseline, your prescriber may prefer a non-oral route (patch, ring, or IUD-only contraception) to avoid adding hepatic load.

Hormone replacement therapy (HRT) in standard menopausal doses is not associated with clinically significant ALT elevation, particularly when delivered transdermally. Oral estradiol has a higher first-pass hepatic effect than transdermal formulations, so transdermal routes are generally preferred when liver function is a concern.

Tamoxifen, used for breast cancer treatment and prevention in premenopausal women, is a well-documented cause of hepatic steatosis and MASLD. A systematic review found that tamoxifen-associated NAFLD occurred in up to 43% of patients. Women starting tamoxifen should have a baseline ALT and repeat testing at 6 and 12 months.

Psychiatric Medications

Several psychiatric medications disproportionately prescribed to women, including valproate (for bipolar disorder, migraine prevention, and epilepsy), can cause dose-dependent hepatotoxicity. The FDA black box warning for valproate specifically flags hepatotoxicity risk, and ALT should be measured at baseline and periodically during treatment. An ALT above 3× ULN in a woman on valproate requires prompt dose review.

MASLD in Women: The Condition ALT Most Often Signals

Metabolic-associated steatotic liver disease is no longer a niche hepatology diagnosis. It is the most common liver disease in women with PCOS, obesity, type 2 diabetes, or metabolic syndrome, and ALT is frequently the only abnormal lab before imaging confirms hepatic steatosis.

The WomanRx ALT-to-Action Framework for Women

Standard clinical algorithms for elevated ALT were not designed with female-specific thresholds or hormonal context in mind. Based on current sex-specific evidence, here is how to approach an elevated ALT result as a woman:

Step 1. Verify the threshold. Compare your ALT to the sex-specific ULN of ~19 to 25 U/L, not just the printed lab range. An ALT of 30 U/L is elevated for a woman even when the report says "normal."

Step 2. Identify life-stage context. Are you pregnant? Perimenopausal? On tamoxifen? Each context changes the differential and the urgency.

Step 3. Screen for MASLD drivers. Fasting glucose, hemoglobin A1c, fasting lipids, and a hepatic steatosis index or FIB-4 score can stratify risk without imaging.

Step 4. Check current medications. Review everything, including supplements (high-dose niacin, green tea extract, and kava are common culprits in women using over-the-counter wellness products).

Step 5. Decide on medication adjustments using multiples of the sex-specific ULN, not the printed range.

PCOS and MASLD: A Particularly High-Risk Intersection

Women with PCOS have multiple overlapping MASLD risk factors: hyperinsulinemia, androgen excess, dyslipidemia, and often central adiposity. A 2023 study in Fertility and Sterility found that insulin resistance, not BMI alone, was the strongest predictor of elevated ALT in women with PCOS. This means a lean woman with PCOS and insulin resistance can have an elevated ALT at a BMI well below 25, and her risk should not be dismissed on the basis of weight alone.

How to Lower a High ALT

Lowering ALT requires treating the underlying cause. No supplement or diet change reliably lowers ALT without also reducing the hepatic injury driving the elevation. Evidence-based interventions exist.

Weight Reduction

A 5 to 10% reduction in body weight reduces hepatic steatosis and lowers ALT in women with MASLD. The PREDIMED-Plus trial and subsequent meta-analyses confirm that a 7 to 10% weight loss reduces ALT by approximately 30 to 40% in patients with NAFLD. GLP-1 agonists, by producing sustained weight loss alongside direct hepatic effects, are currently the most evidence-backed pharmacological approach.

Dietary Changes

A Mediterranean-style dietary pattern, specifically one lower in saturated fat, refined carbohydrates, and added sugar, is the dietary intervention with the most consistent ALT-lowering data. Fructose restriction deserves particular mention: dietary fructose drives de novo lipogenesis in the liver and is a direct contributor to steatosis. Cutting out sugar-sweetened beverages alone has produced measurable ALT reductions in short-term trials.

Exercise

Aerobic exercise reduces liver fat independent of weight loss. A meta-analysis in JAMA Internal Medicine found that 150 to 240 minutes per week of moderate-intensity aerobic exercise reduced liver fat content by approximately 19 to 26%, with corresponding ALT improvements. Resistance training also reduces hepatic steatosis and may be particularly relevant for post-menopausal women managing sarcopenic obesity.

Vitamin E

The PIVENS trial found that vitamin E (800 IU/day) improved liver histology in non-diabetic adults with biopsy-proven NASH, and ALT fell significantly in the treatment group. The AASLD currently recommends vitamin E as a pharmacological option for non-diabetic women with biopsy-proven MASH. It should not be used at high doses during pregnancy.

When a Low ALT Matters

A very low ALT (below 7 U/L, or near undetectable) rarely gets clinical attention but can be meaningful. Severe protein-energy malnutrition depletes the substrate needed to produce ALT, so a paradoxically low ALT in a cachectic or severely malnourished woman may mask significant hepatic inflammation. Pyridoxine (vitamin B6) deficiency also suppresses ALT production. Women with restrictive eating patterns or bariatric surgery may see falsely low ALT values for this reason. This evidence gap is real: low ALT as a clinical signal in women with eating disorders has not been well studied.

Pregnancy and Lactation: What ALT Changes About Your Care

Because this is not a drug article, there is no pregnancy category or lactation transfer to assign to ALT itself. However, ALT results during pregnancy and breastfeeding directly determine which medications you can and cannot take, making this section mandatory.

Pregnancy

Normal ALT in pregnancy is modestly lower than the non-pregnant reference range, particularly in the first and second trimesters, because hemodilution reduces enzyme concentrations in plasma. An ALT that appears within the standard printed range during pregnancy may therefore still be relatively elevated for gestational status.

Conditions that cause pathological ALT elevation in pregnancy include:

• Intrahepatic cholestasis of pregnancy (ICP): ALT can reach 2 to 10× ULN; associated with preterm birth and stillbirth; requires bile acid measurement and obstetric co-management.
• HELLP syndrome: Occurs in 0.5 to 0.9% of all pregnancies; ALT can exceed 10× ULN; obstetric emergency.
• Acute fatty liver of pregnancy (AFLP): Rare but life-threatening; occurs in the third trimester; ALT is elevated alongside coagulopathy and hypoglycemia.

None of these conditions are managed primarily through ALT-lowering medications. They require obstetric intervention, sometimes urgent delivery.

ACOG Practice Bulletin 230 provides detailed guidance on liver disease in pregnancy.

Lactation

Women who are breastfeeding and have an elevated ALT should have the underlying cause identified before any hepatotoxic medication is prescribed. The medications used to treat MASLD or liver disease in non-pregnant women vary considerably in their lactation safety profiles. Vitamin E at supplemental doses is generally considered compatible with breastfeeding. GLP-1 agonists have limited lactation data; the FDA labels for semaglutide and liraglutide advise against use during breastfeeding due to the absence of safety data, not confirmed harm.

Who This Is Right For (and Not Right For): ALT Monitoring by Life Stage

ALT monitoring is appropriate for any woman who:

• Takes a medication with hepatotoxic potential (statins, valproate, tamoxifen, metformin in active liver disease, antifungals, antituberculars)
• Has PCOS, metabolic syndrome, type 2 diabetes, or obesity
• Is perimenopausal or post-menopausal with any metabolic risk factor
• Has a personal history of autoimmune disease, thyroid disease, or a first-degree relative with liver disease
• Uses high-dose supplements including niacin, green tea extract, or herbal weight-loss products

ALT monitoring is less urgent (but not irrelevant) for:

• A healthy woman in her 20s or 30s with no metabolic risk factors, no hepatotoxic medications, and no symptoms
• A woman whose ALT is mildly elevated due to strenuous exercise in the 24 to 48 hours before the blood draw (exercise-induced ALT elevation is transient and typically resolves within 72 hours)